CD8A and neoplasm: Wilmott et al. demonstrated an increase in CD8+ and CD4+ T cells in patient tumor samples collected one week after treatment with BRAF inhibition, with magnitude of CD8+ T-cell influx correlating with tumor necrosis and size reduction [132].